INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 424m ago
HOUSE PTR24m ago
SEC 13F24m ago
ROBINHOOD CHAIN24m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Meyer Andrew Hollman reported JANX

Chief Business Officer · Janux Therapeutics, Inc. · Common Stock

Side
M
Value
$35K
Shares
3,333
Price
$10.59
Executed
Nov 14, 2025
Disclosed
Nov 14, 2025
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Nov 14 executedNov 14, 2025 disclosed

JANX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

    $35K reported value · 3.9% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · JANX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    28
    DN
    Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$57K
    4,059 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$29K
    2,038 sh
    		May 11, 2026May 13, 2026
    traded May 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GW
    Go WilliamChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    44.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GW
    Go WilliamChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    154.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    40
    MZ
    McIver ZachariahChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$37K
    2,714 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    21
    MZ
    McIver ZachariahChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    29.0K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    21
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    18.9K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    42.6K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    17
    DT
    DiRaimondo ThomasChief Scientific Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    31.4K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DT
    DiRaimondo ThomasChief Scientific Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    109.9K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    17
    WM
    Winter Charles M.Chief Technical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    28.6K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    WM
    Winter Charles M.Chief Technical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    100.1K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    17
    CA
    Campbell David AlanDirector, President and CEO
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    96.6K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CA
    Campbell David AlanDirector, President and CEO
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    338.1K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    126.0K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    40
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$20K
    1,462 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    36
    WM
    Winter Charles M.Chief Technical Officer
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$33K
    2,401 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    36
    DT
    DiRaimondo ThomasChief Scientific Officer
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$34K
    2,505 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    39
    CA
    Campbell David AlanDirector, President and CEO
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$111K
    8,072 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    21
    DN
    Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    36.0K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001864159-25-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 14, 2025
    Published
    Nov 14, 2025
    Ingested by INSIDER
    Nov 5, 04:33 UTC
    Last re-read
    Nov 5, 04:33 UTC

    Extracted facts

    Filer
    Meyer Andrew Hollman
    Role
    Chief Business Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Janux Therapeutics, Inc.
    Ticker
    JANX
    Shares
    3,333
    Price per share
    $10.59
    Value
    $35,296
    Execution date (reported)
    Nov 14, 2025
    Owned after transaction
    88.3K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 3,333
    • Price: $10.59

    = $35,296

    What this establishes

    Meyer Andrew Hollman filed this Form 4 reporting a option exercise of JANX on Nov 14, 2025. It became public on Nov 14, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Business Officer
    Meyer Andrew Hollmancik:0001864159
    Issuer
    Janux Therapeutics, Inc.cik:0001817713

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.